; (B) the adult's neurologist attests that other treatment options have not resulted in significant clinical improvement; (C) the adult’s neurologist attests that he or she has discussed the currently known potential harms and benefits of using cannabidiol or other nonpsychoactive components of marihuana as a treatment with the adult; (D) the adult’s neurologist attests that he or she will monitor the adult for potential adverse reactions; and (E) the adult provides documentation for the requirements under subparagraphs (A), (B), (C), and (D); or (3) a State-licensed physician to discuss the currently known potential harms and benefits of cannabidiol or any other nonpsychoactive component of marihuana as a treatment with a patient of the physician, or the legal guardian of the patient if the patient is a child. (c) Sunset This section shall cease to have force or effect on the date that is 4 years after the date of enactment of this Act. 8. Federal research The Secretary of Health and Human Services, either directly or through awarding grants, contracts, or cooperative agreements to covered institutions of higher education, medical or osteopathic schools, or practitioners, or a consortia of covered institutions of higher education, medical or osteopathic schools, or practitioners, shall expand, intensify, and coordinate the activities of the National Institutes of Health with respect to research on cannabidiol and other nonpsychoactive components of marihuana to better determine their potential therapeutic effects on serious medical conditions, including intractable epilepsy.